Little is known about the biological mechanisms underpinning the pathology of schizophrenia. We have analysed the proteome of stimulated and unstimulated peripheral blood mononuclear cells (PBMCs) from schizophrenia patients and controls as a potential model of altered cellular signaling using liquid-chromatography mass spectrometry proteomic profiling. PBMCs from patients and controls were stimulated for 72 h in vitro using staphylococcal enterotoxin B. In total, 18 differentially expressed proteins between first-onset, antipsychotic-naive patients and controls in the unstimulated and stimulated conditions were identified. Remarkably, eight of these proteins were associated with the glycolytic pathway and patient-control differences were more prominent in stimulated compared with unstimulated PBMCs. None of these proteins were altered in chronically ill antipsychotic-treated patients. Non-linear multivariate statistical analysis showed that small subsets of these proteins could be used as a signal for distinguishing first-onset patients from controls with high precision. Functional analysis of PBMCs did not reveal any difference in the glycolytic rate between patients and controls despite increased levels of lactate and the glucose transporter-1, and decreased levels of the insulin receptor in patients. In addition, subjects showed increased serum levels of insulin, consistent with the idea that some schizophrenia patients are insulin resistant. These results show that schizophrenia patients respond differently to PBMC activation and this is manifested at disease onset and may be modulated by antipsychotic treatment. The glycolytic protein signature associated with this effect could therefore be of diagnostic and prognostic value. Moreover, these results highlight the importance of using cells for functional discovery and show that it may not be sufficient to measure protein expression levels in static states.
Introduction
Despite extensive research into schizophrenia, questions remain unanswered about the biological mechanisms underlying the disease pathology. Investigations have been hampered due to the complex and multifaceted nature of the illness that is manifested as a diverse spectrum of symptoms ranging from cognitive deficits to behavioural and emotional distortions. Patients suffer from impaired social cognition and communication skills, poor physical health and have a higher risk of committing suicide compared with the general population. 1 Although such clinical information is important, it is not sufficient for improving current diagnostic procedures as it does not alleviate the problem of subjectivity. However, it is likely that behavioural abnormalities are reflected at the molecular level, and as schizophrenia is a multi-factorial disorder 2 these biological abnormalities could be manifested not only in the brain but also in genetic and proteomic signatures present throughout the body tissues and biofluids including the endocrine organs, cerebral spinal fluid, blood serum and cells.
Screening studies conducted at the genetic level have revealed a few credible risk gene candidates for schizophrenia, although most of the findings have not been replicated. 3 The onset and progression of the clinical phenotype is not likely to be due to genetic alterations alone as the complexity of the disorder suggests that multiple genes are involved. Moreover, the prevailing hypotheses suggest that the progressive nature of the illness is manifested through the interaction of genes with environmental factors. 4 To capture both genetic and environmental changes, many researchers have studied the disorder using proteomic platforms. Early studies using these technologies focused on post-mortem brain tissues and identified abnormal expression of proteins associated with several biochemical pathways including metabolism and the immune system. 5, 6 However, these effects are likely to be confounded by antipsychotic drug treatment, poor diet and unhealthy life style associated with chronic stages of the disease. 7 A recent study by Guest et al. 8 showed that insulin and insulin-related peptide levels were increased in serum of first-onset, antipsychotic-naive (AN) patients indicating that metabolic abnormalities may already be present before disease manifestation.
In this study, we established proteomic signatures using liquid-chromatography mass spectrometry (LC-MS E expression mode) profiling for unstimulated and stimulated peripheral blood mononuclear cells (PBMCs) isolated from first-onset AN schizophrenia patients. Unstimulated PBMCs from antipsychotictreated (AT) chronically ill schizophrenia patients were also investigated by LC-MS E to determine which markers may be normalized by treatment and which may be indicators of the underlying disease state. PBMCs were chosen as the tissue source in this study due to reports of immune dysfunction in schizophrenia patients 9, 10 and as previous studies have shown that such cells are useful peripheral sources of biomarkers for studies of psychiatric illnesses. 11, 12 In addition, numerous studies have shown that the brain and blood cells show a number of parallel responses, which suggest that the PBMCs may be a useful surrogate of brain function. 13, 14 To investigate peripheral metabolic and immunological alterations associated with the onset of disease, we also stimulated PBMCs from AN patients in vitro and then analysed these using LC-MS E profiling. Stimulation of PBMCs results in activation of various signaling cascades including the triggering of metabolic pathways 15 and could help identify subtle differences in cell function including changes in the proteome. 16 The resulting proteomic fingerprints were characterized by functional analysis in silico and validated by mechanism of action studies in vitro.
Materials and methods

Study population and demographics
The study was approved by the local ethics committee and conducted from 2007 to 2009 at the University Hospital of Cologne. Subjects comprised 12 first-onset AN patients having first-episode paranoid psychosis (Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV): 295.30) and 7 chronically ill AT patients (DSM-IV: 295.30), as well as 19 healthy controls (HC) with no family history of schizophrenia or detectable medical, psychiatric or neurological problems (Table 1 ). HCs were matched for age, gender, smoking, ethnicity, cannabis use, body mass index and education. Psychopathology was assessed on the day of blood withdrawal. In addition, a validation cohort comprising 8 AN, 7 AT schizophrenia patients and 13 HC subjects was recruited. All participants were screened for medical disorders such as diabetes, heart disease, thyroid disease, autoimmune disease, recent infections or current or previous psychiatric illnesses using DSM-IV criteria and gave written informed consent.
PBMC and serum preparation
Blood was collected into 9 ml EDTA S-Monovette tubes (Sarstedt, Leicester, UK). PBMCs were isolated by density-gradient centrifugation at 750 g for 20 min using Ficoll-Paque Plus (GE Healthcare, Amersham, UK) and washed in Dulbecco's phosphate-buffered saline (Invitrogen, Paisley, UK). Cells were stored in 90% fetal calf serum (Sigma, Dorset, UK) and 10% dimethyl sulfoxide (Sigma) in liquid nitrogen before use. For serum, blood was collected into 7.5 ml S-Monovette tubes (Sarstedt). The tubes were placed at room temperature for 2 h for blood coagulation, 
Subcellular fractionation
Subcellular fractions were prepared from unstimulated and stimulated PBMC pellets along with quality control samples (n = 8) aliquoted from a single donor. Protein intensity measurements were used to assess variability of the preparation, fractionation and mass spectrometric stages of the procedure. PBMC cytosolic fractions were produced using the ProteoExtract Subcellular Proteome Extraction Kit according to the manufacturer's specifications (Merck, Darmstadt, Germany). The resulting subcellular composition was 71 and 59% soluble proteins in the unstimulated and stimulated samples as determined by Swiss-Prot annotation. Note that only soluble proteins were analysed to keep sample running times under 3 weeks as, after this period, MS detection sensitivity varies between 10 and 15% introducing noise into the data set that might hamper data quality. 17 Protein concentrations were measured using the Bio-Rad DC Protein Assay (Bio-Rad, Hercules, CA, USA). Proteins were digested using the ProteoExtract All-In-One Trypsin Digestion Kit (Merck) according to the manufacturer's protocol with minor changes. In brief, 4 ml trypsin (Promega, Southampton, UK) was added to samples after addition of blocking agent and samples were incubated for 17 h at 37 1C with shaking. The reactions were terminated by addition of 1.1 ml 8.8 M HCl (Sigma) and samples stored at À80 1C until MS analysis.
LC-MS
E and data analysis The LC-MS E profiling study was carried out in expression mode (for detailed description refer to Levin et al. 17 ) and data acquired as described previously. 17 Resulting data were processed with the ProteinLynx Global Server software version 2.3 (Waters Corporation, Milford, MA, USA) and searched against the human Swiss-Prot v55 protein database (SIB Switzerland) that contained 349 480 sequence entries as described previously. 17 The total ion current was used for data normalization. The mean intensity coefficient of variation of all proteins detected in the cytosolic fraction of quality control samples was 27%. Processed LC-MS E data were exported to the software package R (http://cran.rproject.org) for filtering and protein intensities were calculated based on methods described previously. 17 In brief, criteria for inclusion required the appearance of a peptide in at least two out of three injections per sample and in at least 80% of samples in any of the groups. Calculation of protein abundance was based on correlating peptides with a cut-off set to 0.49 (Pearson's correlation). 18 Standard statistical methods were used to investigate data structure and to test for potential experimental artefacts, the need for transformation or exclusion of outlying data. Student's ttest was applied to identify differentially expressed proteins (P < 0.05). SIMCA-P þ 10.5 (Umetrics, Umea, Sweden) was used for principal component analysis (PCA) to determine the degree of overlap across the groups.
In silico pathway analysis For functional categorization and pathway analysis, statistically significant proteins were analysed in silico using the Ingenuity Pathway Knowledgebase software (Redwood City, CA, USA). Assignment of functions and canonical pathways was performed automatically by computational algorithms as described previously. 19 Protein cluster analysis Protein cluster analysis is a useful computational technique that identifies determinants of a disease that have impact through cooperative function. 20 Here, the LC-MS E protein expression results were subjected to factor analysis to reduce the multidimensional data to the factors that have the highest influence on data structure by considering variance and noise. All combinations of these proteins were tested in simulations to identify those that give the greatest separation between patients and controls. The precision of each combination of analytes in separating patients and controls was tested through a corresponding kernel PCA prediction model. Similar to standard PCA, kernel PCA provides a new projection basis that yields maximal variance in descending order by performing eigenvalue decomposition on the data covariance matrix. 21 The prediction boundary of a kernel PCA projection is determined using Fisher's discriminant analysis. To assess prediction power, we built each kernel PCA model a randomly selected training set consisting of half patient and half control sample data and then tested on a set consisting of the remaining data (Supplementary Figure S1 ).
Validation studies Immunoblot analysis. Differential expression of selected proteins identified by LC-MS E analysis
Impaired glycolytic function in schizophrenia M Herberth et al was tested further by immunoblot analysis using soluble PBMC fractions prepared from a separate validation cohort (five AN schizophrenia, five AT schizophrenia and five HC subjects; Table 1 ) and primary antibodies against the proteins listed in Table 2 . All antibodies were purchased from Abcam (Cambridge, UK). Detection and quantification were performed using the Odyssey Infrared Imaging System (LI-COR, Cambridge, UK). Intensities of immunoreactive protein bands were normalized to those of the b3-tubulin immunoreactivity in each track.
Insulin/glucose. Assays were performed in duplicate by the NIHR Cambridge Biomedical Research Centre, Core Biochemistry Assay Laboratory, Addenbrooke's Hospital, and the necessary reagents and calibrants were provided as described previously. 22 In brief, glucose levels were determined spectrophotometrically in 25 ml serum obtained from 12 AN, 8 AT schizophrenia and 19 HCs (same subjects as for LC-MS E profiling study) using an adaptation of the hexokinase-glucose-6-phosphate dehydrogenase method on a Dimension RXL Clinical Chemistry System (Dade Behring, Milton Keynes, UK). Insulin levels were determined in 25 ml of serum obtained from the same subjects using a two-step time-resolved fluorometric assay from PerkinElmer (Beaconsfield, Bucks, UK).
Lactate measurement. Lactate concentrations were measured in duplicate in supernatants of stimulated PBMCs (same subjects as for LC-MS E profiling study) using an assay kit (Biovision, Mountain View, CA, USA). In brief, 50 ml of cell supernatants were transferred in duplicate to a 96-well flat-bottom plate. Reaction mix buffer (50 ml; lactate enzyme and substrate) was added to the supernatants and incubated for 30 min at room temperature. The results were quantified at 450 nm using a plate reader (Bio-Rad, Birmingham, UK).
Hexokinase activity. Hexokinase activity (Sigma) was measured in triplicate in supernatants of lysed PBMCs obtained from the validation cohort (eight AN schizophrenia and eight HC subjects; Table 1 ). Cell pellets were re-suspended in 230 ml homogenization buffer (150 mM KCl, 5 mM MgCl 2 , 5 mM EDTA, 5 mM b-mercaptoethanol), incubated on ice for 30 min and centrifuged at 13 000 g for 5 min. In a spectrophotometer cuvette, 2.28 ml Tris/MgCl 2 buffer, 0.5 ml 0.67 M glucose, 0.1 ml 16.5 mM ATP, 0.1 ml 6.8 mM NAD and 0.01 ml G6PD were mixed and pre-heated at 30 1C for 6 min, followed by addition of 0.1 ml of the cell supernatants. Hexokinase activity was based on reduction of NAD þ in the presence of G6PD and determined spectrophotometrically by recording the increase in absorbance at 340 nm over 10 min. Statistical analysis. Statistical analysis for all functional validation assays was performed using two-tailed t-test in Prism version 5 (GraphPad Software, La Jolla, CA, USA). P-values of < 0.05 were considered statistically significant.
Results
PBMC proteome profiling
Peripheral blood mononuclear cells isolated from AN (n = 12) and AT (n = 7) schizophrenia patients and HC subjects (n = 19), consisted of > 75% lymphocytes as determined by flow cytometric analysis. No differences in subpopulations of T cells, NK cells, B cells and monocytes were found between schizophrenia patients and HC subjects (data not shown). PBMCs were subjected to subcellular fractionation to enrich soluble proteins. In the unstimulated condition PMBCs from all volunteers were analysed on the LC-MS E whereas in the stimulated condition only PBMCs from AN patients and HCs were analysed as the primary aim was to identify differentially expressed proteins in the first stages of the disease to eliminate medication effects. LC-MS E analysis identified 5141 and 7713 peptides (Supplementary data) in unstimulated and stimulated PBMCs, which translated to 185 and 441 non-redundant proteins, respectively, using the Swiss-Prot database. In total, 18 differentially expressed proteins between AN patients and HCs were identified. Of these, 6 proteins were altered in unstimulated PBMCs, 13 proteins were altered after stimulation with SEB þ CD28 and 1 protein (lactate dehydrogenase B; LDHB) was altered in both the conditions ( Table 3 ). Note that all proteins, with the exception of CH60, showed increased expression in stimulated PBMCs from AN patients compared with those from HC subjects. None of the proteins that showed significant differences in expression between unstimulated PBMCs from AN and HC subjects was altered in AT patients with the exception of coactosin-like protein (COTL1) that was also significantly decreased in these patients (P = 0.03; data not shown). Only those differentially expressed proteins initially identified between AN patients and HCs were considered in AT patients as the identification of differentially expressed proteins between AT patients and HCs would have been confounded by medication effects.
Principal component analysis was used to determine whether a separation according to diagnostic group can be achieved based on the differentially expressed proteins. PCA reduces multidimensional data sets by performing spectral decomposition analysis on covariance matrices. We considered the first two dimensions (principal components 1 and 2) that represent the greatest variance/information content of the data set. 23 AN patients showed good separation from HC subjects for unstimulated PBMCs and a greater separation for stimulated PBMCs ( Figure  1 ). In contrast, AT patients differed from AN patients in that they clustered more closely with the HC subjects.
Characterization of differentially expressed proteins in silico Ingenuity pathway analysis. The Swiss-Prot accession codes of differentially expressed proteins were uploaded into the Ingenuity Pathway Knowledgebase database to obtain information on relevant biological functions. The most significant (P = 9.46EÀ04) canonical pathway associated with the differentially expressed proteins (GPI, LDHB) in unstimulated PBMCs was glycolysis. The same pathway was also the most significant (P = 1.6EÀ11) for stimulated PBMCs, and was associated with a higher number of differentially expressed proteins (LDHB, PGK1, ALDOC, TPIS, GAPDH, PGAM4, Pyruvate kinase isozyme R/L [PKLR]; Figure 2 ). Aldolase C (ALDOC) and triosephosphate isomerase (TPIS) were also significantly associated with the fructose/mannose (P = 5.32EÀ04) and inositol (P = 1.05EÀ03) metabolism.
Protein cluster analysis. To investigate the potential differential effects on glycolysis further, we applied a non-linear multivariate statistical approach to identify combinations of glycolytic proteins that have high precision for distinguishing patients from controls (Supplementary Figure S1) . The top 20 protein combinations producing the best prediction models for separating AN patients from HC subjects were identified. The median precision prediction values were obtained after 1000 simulation tests for all combinations to avoid biased predictions associated with small sample sizes. The clusters generally gave lower prediction values for unstimulated compared with stimulated PBMCs, supporting the case that glycolysis is linked to immune response (Table 4) . This is also consistent with previous studies that have shown that glycolysis in immune cells is triggered after stimulation in vitro. 24 The same general result was obtained using sample sets of equal sizes (seven HC, seven AN) to Impaired glycolytic function in schizophrenia M Herberth et al confirm that there was no bias introduced by different sample sizes (data not shown). Clusters involving enolase 1 (ENO1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gave high precision results for the stimulated samples although ENO1 was initially not found by LC-MS E to be differentially expressed in patients. This shows the power of the techniques for identifying molecules that show patterned behaviour. To confirm that these clusters were specific for the stimulated state, we chose the top five clusters for stimulated PBMCs and used these to predict the diagnostic group of the unstimulated samples. This showed that the prediction results were consistently lower for unstimulated PBMCs (Table 4) .
Functional validation
Immunoblot validation of differentially expressed proteins. As the main outcome of the LC-MS E analysis was the high number of altered glycolysisrelated proteins, selected biomarker candidates associated with this pathway were also measured by immunoblot analysis using an independent PBMC sample cohort composed of five AN and five AT patients as well as five HC subjects (Table 1) .
Reproducibility was assessed by comparing the fold changes obtained from the LC-MS E and immunoblot analyses ( Table 2 ). In unstimulated PBMC samples, increased expression levels of cytosolic non-specific dipeptidase 2 and LDHB were confirmed when comparing AN patients with HC subjects. Expression levels of these proteins did not differ between AT patients and HC subjects, consistent with the LC-MS E results. In contrast, decreased expression levels of glucose 6-phosphate isomerase (GPI) in AN patients was not confirmed by immunoblot analysis (Table 2 ). In stimulated PBMC samples, increased expression of TPIS, GAPDH and LDHB was confirmed by immunoblot analysis although that of ALDOC and phosphoglycerate kinase 1 (PGK1) was not. Note that most of the findings did not reach statistical significance (P < 0.05) as immunoblot validation was carried out using only five samples per group. However, many of the changes showed borderline significance and all, except for ALDOC, showed consistent directional changes with those found in the LC-MS E profiling study.
Serum analytes.
Insulin signaling regulates glycolysis in most tissues. 25 As the majority of the Impaired glycolytic function in schizophrenia M Herberth et al differentially expressed proteins that we identified are associated with glycolysis, the circulating serum levels of insulin and glucose were measured in the same subjects from which the PBMCs were derived. Glucose levels were not significantly different between AN and HC subjects (P = 0.3) and were in the normal range of glycaemia ( < 7.8 mmol l À1 ) ( Figure  3A ). This is an important indicator as the patients were not fasted at the time of blood withdrawal. In contrast, insulin levels were increased 1.5-fold in AN patients compared with HC subjects (P = 0.0013), confirming previous findings. 8 Neither glucose nor insulin levels were significantly different in chronically ill AT patients.
PBMC insulin signaling markers. Engagement of the T-cell receptor and co-ligation with CD28 leads to enhanced glucose transport and glycolysis. 26 In lymphocytes, the major glucose transporter and regulator of glucose uptake is GLUT1, an insulinindependent transporter that is upregulated on the cell surface after T-cell stimulation. 26 We therefore analysed the expression of GLUT1 and the IR using stimulated PBMCs from eight AN patients and eight HC subjects (Table 1 ). The percentage of GLUT1-expressing PBMCs was increased 1.3-fold in AN patients when compared with HCs (P = 0.022) and the percentage of PBMCs expressing the IR was decreased 1.1-fold in the same subjects (P = 0.017) ( Figure 3B ).
PBMC glycolysis markers.
The alterations in GLUT1 expression described above and the expression changes in glycolytic proteins are not sufficient to explain a functional change in glycolysis. Glucose uptake and the role of glucose within a cell are regulated by phosphorylation of glucose and this process is controlled by hexokinase. Therefore, the activity of this enzyme was measured in supernatants of lysed stimulated PBMCs obtained from eight AN patients and eight HC subjects (Table 1) . No difference was observed in hexokinase activity between the two groups (P = 0.9; data not shown). In addition, we measured lactate levels in cell supernatants of stimulated PBMCs as previous studies have shown that induction of glycolysis results in production and secretion of lactate from lymphocytes. 27 Figure 3C shows that lactate levels were significantly increased in AN patients compared with HC subjects (P = 0.014).
Discussion
The aim of this study was to identify altered proteomic signatures and molecular pathways to broaden our understanding of the pathophysiology underlying schizophrenia throughout different stages of the disease. PBMCs from first-onset AN and from chronically ill AT patients were profiled using a nonhypothesis-driven LC-MS E screening approach. It was important to include different patient subtypes as the aetiology and pathology are not known and the course Proteomic profiling of unstimulated PBMCs resulted in the identification of 6 proteins that were differentially expressed between the first-onset patients and controls, whereas 13 differentially expressed proteins were identified after stimulation. Eight of these proteins were associated with glycolysis and were altered predominantly only in the case of the stimulated PBMCs. None of these proteins, with the exception of COTL1, showed differential expression in unstimulated PBMCs when comparing the chronically ill AT patients with controls, suggesting that at least some of these proteins may be normalized under long-term disease conditions or by treatment with antipsychotic medications. Changes seen in COTL1 were interesting as this protein has been previously associated with autoimmune disorders. 28 Considering the association of this protein with F-actin, changes in COTL1 expression could be indicative of effects on cytoskeletal re-organization. 29 Also, differential protein expressions of ALDOC, GAPDH, PGAM, HNRPK, PGK1 and PPIA in schizophrenia brain tissue have previously been reported, further supporting our findings. 30, 31 Further longitudinal studies should be carried out to determine whether these could be suitable as biomarkers for distinguishing patients from controls at the earliest stages of the disease or as responsive markers for monitoring antipsychotic treatment status. However, as sample numbers were low, it will be necessary to validate these findings using larger sample cohorts and samples from patients before and after drug treatment. Moreover, it would be of interest to investigate protein signatures in stimulated PBMCs obtained from various schizophrenia subtypes. We showed that cellular/immunological conditions such as stimulation of PBMCs is recommended for these studies as this appeared to increase the separation between the disease and control states. These results highlight the importance of using cells for functional discovery of molecular pathways and show that it may not be sufficient to measure cellular protein expression levels in unstimulated states. The effect on HSP72 in unstimulated PBMCs was intriguing considering that single nucleotide polymorphisms in this gene have been linked previously to schizophrenia, 32 and expression of the gene has been shown to be altered in post-mortem brain of patients with schizophrenia. 33 Also, alterations in expression of the protein have been associated previously with mitochondrial dysfunction in PBMCs. 34 Here, protein clusters involving ENO1, GAPDH, GPI, PGM2 and TPIS, which are all key enzymes of the glycolysis pathway, resulted in the highest precision values for this separation between disease and control in stimulated cells.
Glycolysis provides the energy for immune cells to exert a full immune response 35 by acquiring metabolic substrates such as glucose from the circulation. 15 However, immune cells are not capable of regulating the uptake of circulating metabolic substrates autonomously but instead this is controlled by hormones, cytokines or engagement of antigen and co-stimulatory receptors. 15 In this study, circulating glucose levels in first-onset patients were relatively normal although insulin levels showed a significant elevation. This suggested that at least some of these patients were insulin resistant, consistent with our recent findings of elevated levels of insulin and other insulin-related peptides in a different cohort of patients. 8 This means that the bioenergetic demands that maintain normal cellular functions in vivo, such as glucose uptake, activation of glycolysis and general regulation of insulin signaling, require increased secretion of insulin from pancreatic b-cells. This has important implications as numerous studies have suggested that too much insulin can have deleterious effects on brain function. 36 For example, hippocampal volumes appear to be reduced in diabetic patients and in insulin-resistant individuals with high circulating insulin levels. 37 Also, hyperinsulinaemia has been implicated in the pathogenesis of Alzheimer's disease and associated with phenomena such as aberrant phosphorylation of filamentous proteins, translocation of signaling molecules, increased central nervous system inflammation and b-amyloid plaque deposition. 38 The normal mechanism of stimulation by activation of the CD28 co-receptor triggers signaling cascades that overlap with those induced by binding of insulin to its receptor. In this case, stimulation resulted in increased expression of glycolytic proteins in firstonset schizophrenia patients, along with increased numbers of GLUT1-expressing and decreased numbers of IR-expressing PBMCs. Although the increased GLUT1 expression suggests that glucose uptake might also be increased, it does not necessarily suggest an increase in glycolytic flux as this is controlled mainly by phosphorylation of hexokinase, one of the main rate-limiting enzymes in the glycolytic pathway. 27 Consistent with this, we did not find any change in hexokinase activity in the first-onset patients. However, it is possible that the observed increase in expression of glycolytic proteins and increased production of lactate may compensate for perturbations of this pathway. A previous report from our group showed decreased expression of glycolytic proteins at the transcriptomic level and increased lactate concentrations in the prefrontal cortex of schizophrenia subjects. 39 Glycolysis is a fundamental feature of all cells and is therefore associated with a range of cellular responses that have been associated with schizophrenia. This includes effects on the immune system, 35 cytoskeletal abnormalities, 40 synaptic plasticity 41 and neurogenesis. 42 Abnormalities in glucose metabolism and the link to metabolic syndrome in schizophrenia patients have been known for decades 7 with evidence deriving from genes associated with glycolysis and signs of abnormal glucose metabolism, including changes in glucose transporter expression. 12, 43 It has been believed for decades that the link between metabolic syndrome and schizophrenia derives solely from side effects of antipsychotic medications. 44 However, a study by Stone et al. 43 supports the view that glycolytic abnormalities are inherent to the disease rather than deriving solely from environmental or pharmacological influences, as shown in this study. We also show that insulin levels are elevated before disease manifestation and we demonstrate for the first time that patients' cells, most likely deriving from an insulin-resistant environment, are compromised at the level of glycolysis when stimulated in vitro.
In this study, we have identified biomarkers associated with altered immune response, which can be useful for distinguishing schizophrenia subjects from HC. Similar studies of other psychiatric disorders with overlapping symptoms are required to determine whether these effects are specific for schizophrenia. This is important, as it is possible that the observed effects represent the proteomic profile of a more generalized neurological or neurodegenerative process. Two of the enzymes reported in this study, ALDOC and TPIS, have been shown to be altered in the brains of subjects with varying disorders such as schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's disease. 45 In addition, enolase-associated pathways have been linked to neurodegenerative disorders. 46 One note of caution that should be addressed arises from the small sample numbers used in this study. These were limited by the fact that large clinical centres (B1500 patients) recruit only 10-20 AN patients per year who are free of substance abuse or comorbidities such as heart and thyroid diseases or type II diabetes. The small number of samples did also not allow for internal subgroup comparisons. Arbitrary division of the groups would result in a loss of statistical power and is, therefore, unlikely to provide meaningful results. In addition, there is a technical complication associated with the fact that high numbers of samples require running periods over several weeks on the LC-MS E system. Running times longer than 3 weeks can result in alterations in sensitivity of detection by 10-15%, reducing the data quality. 17 Further limitations of the study include the small fold changes obtained for differentially expressed proteins. This is most likely due the small sample numbers, the non-homogeneous cell composition of PBMCs and the heterogeneity of the disorder, which most probably consists of a wide spectrum of related conditions with overlapping symptomology. It is also possible that the differences in the proteomic response after stimulation may represent a primary alteration in the immune response in schizophrenia subjects, which leads to the observed alterations in glycolysis under the additional burden of immune activation. 47 However, it is likely that the current results are valid given the different converging lines of evidence that suggest alterations in the insulin signaling and glycolytic pathways. Furthermore, we used a non-linear multivariate statistics method that confirmed that glycolysis was a major pathway affected in the disorder. Moreover, this analysis showed that even biomarkers that have only subtle or non-significant expression changes show high precision as a cluster for identification of first-onset schizophrenia subjects.
In conclusion, we found increased expression of proteins associated with the glycolysis pathway in first-onset, antipsychotic naive schizophrenia patients. We also showed that small clusters of these proteins can be used to discriminate schizophrenia patients from control subjects with high precision. Most importantly, the alterations in glycolysis were seen to occur predominantly after PBMC stimulation as opposed to the situation in unstimulated cells. This highlights the importance of using functional cell investigations for mechanistic studies in schizophrenia. Using such approaches in future studies could help to identify and verify peripheral signatures and molecular pathways associated with schizophrenia and may generate much-needed biomarkers for diagnostic and prognostic purposes and potentially facilitate the development of novel therapeutics.
